CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Ablation of Peripheral, Genicular and Other Nerves and Neuromas

Defines coverage and prior authorization expectations for radiofrequency ablation and cryoneurolysis of peripheral nerves, genicular nerves, and neuromas for Medicare Advantage and Commercial products offered by Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAblation of Peripheral, Genicular and Other Nerves and Neuromas

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 5, 2026

Next Review DateJan 1, 2026

Key ActionObtain prior authorization via the online tool for Medicare Advantage members (recommended for Commercial) and document medical necessity per the online criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MA coveredMedicare Advantage coverage for genicular nerve ablation

Commercial NMNCommercial stance on genicular ablation

Not coveredCryoneurolysis for knee OA/TKA

Not coveredMinimally invasive ablation for neuromas

PA required

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior authorization requirement (MA)

multipleProcedure & device codes listed

Coverage Criteria and Indications

Product-specific coverage determinations

Coverage stance varies by product (Medicare Advantage vs Commercial); apply product-specific rules:

Medicare Advantage - Peripheral Nerve/Branch Ablation: Peripheral nerve or branch ablation (including radiofrequency ablation and cryoneurolysis) may be considered medically necessary when the criteria in the online prior authorization/Medical Necessity tool are met.

Prior authorization required for Medicare Advantage. Genicular nerve ablation (RFA or cryoneurolysis) is covered. Nerve cryoablation probe and cryoablation needle may be considered medically necessary when the associated procedure is determined to be medically necessary.

Commercial Products - Peripheral Nerve/Branch Ablation: Peripheral nerve or branch ablation may be considered when the criteria in the online tool are met; prior authorization is recommended. Specific procedures are identified as not medically necessary for Commercial Products.

Genicular nerve ablation, cryoneurolysis for knee OA/TKA, occipital neuralgia or cervicogenic headache, and minimally invasive ablation for Morton and other peripheral neuromas are specified as not medically necessary. Cryoablation probes/needles are not medically necessary for Commercial Products.

Coverage considerations by indication

Evidence-based coverage stance summarized by indication:

Genicular RFA/Cryoneurolysis for Knee Osteoarthritis (OA): Randomized trials and systematic reviews show short-term (3–6 month) reductions in pain and improved function in some studies (cooled RFA appears more effective through 6 months), but heterogeneity and limited long-term blinded data (≥12 months) leave net health benefit uncertain.insufficient certainty

See evidence summaries and need for larger, blinded trials with longer follow-up.

Cryoneurolysis prior to or around Total Knee Arthroplasty (TKA): RCTs and observational studies demonstrate transient reductions in pain and opioid use and mixed functional outcomes; evidence insufficient to conclude durable net health benefit beyond short-term endpoints.insufficient certainty

Trials vary in outcomes and follow-up; optimal technique and duration unresolved.

Plantar Fasciitis - RFA:

Cryoneurolysis of peripheral nerves to treat pain associated with knee osteoarthritis (OA) or total knee arthroplasty (TKA) is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products because the evidence is insufficient to determine that the technology results in an improvement in net health outcome. When CPT 64640 is billed, medical necessity review is required to identify the specific procedure performed (eg, RFA versus cryoneurolysis) per the online authorization tool.

Radiofrequency ablation or cryoneurolysis of peripheral nerves for occipital neuralgia or cervicogenic headache is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence that these procedures improve net health outcomes.

The policy lists specific CPT and HCPCS codes with differing coverage status: CPT 64632 and CPT codes 0440T–0442T are identified as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

For Commercial Products, the policy designates several interventions as not medically necessary: ablation of the genicular nerve (radiofrequency or cryoneurolysis) for knee OA, and minimally invasive ablation procedures (including intralesional alcohol injection, RFA, and cryoablation) for Morton neuroma and other peripheral neuromas. Additionally, nerve cryoablation probes and needles are listed as not medically necessary for Commercial Products.

The policy explicitly identifies several procedure and device items as not medically necessary for Commercial Products or as subject to mixed coverage by product: CPT 64624 is covered for Medicare Advantage but not medically necessary for Commercial Products; CPT 64632 and CPT 0440T–0442T are not covered for Medicare Advantage and not medically necessary for Commercial Products; and HCPCS C9808 and C9809 (cryoablation probes/needles) are covered for Medicare Advantage when criteria are met but are not medically necessary for Commercial Products.

Procedure and Billing Codes

Referenced CPTCPT

64640

Destruction by neurolytic agent, other peripheral nerve(s), other than plexus or ganglion; or by other means (used to represent ablation of peripheral nerve but is not method-specific)

May be considered medically necessary (MA & Commercial when criteria met)CPTCovered

64640

Destruction by neurolytic agent; other peripheral nerve or branch

Covered for Medicare Advantage; not medically necessary for Commercial ProductsCPT

64624

Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed

Covered for Medicare Advantage when criteria met; not medically necessary for Commercial ProductsHCPCS

C9808	Nerve cryoablation probe (e.g., cryoICE, cryoSPHERE, cryoSPHERE MAX, cryo2), including probe and all disposable system components, nonopioid medical device
C9809	Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, nonopioid medical device

Not covered / not medically necessaryCPTNot Covered

64632

Destruction by neurolytic agent; plantar common digital nerve

Not covered / not medically necessaryCPTNot Covered

0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve
0442T	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)

Not covered / not medically necessaryCPTNot Covered

0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve
0442T	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)

Covered for Medicare Advantage when criteria met; not medically necessary for Commercial ProductsHCPCS

C9808	Nerve cryoablation probe (e.g., cryoICE, cryoSPHERE, cryoSPHERE MAX, cryo2), including probe and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)
C9809	Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)

Covered for Medicare Advantage; not medically necessary for Commercial ProductsCPT

64624

Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products. Providers must submit prior authorization requests via the payer's online authorization tool and follow the clinical criteria source referenced in the Prior Authorization for Services, Treatments or Procedures policy. Participating providers should confirm authorization requirements and obtain approval prior to scheduling ablation procedures.

Prior authorization submission via online tool (participating providers).
Medicare Advantage: prior authorization required.
Commercial Products: prior authorization recommended.

Documentation Required

Medical Necessity Documentation

Documentation submitted with the authorization request must demonstrate medical necessity per the online authorization tool and the payer's Medical Necessity policy. Include relevant clinical information such as diagnosis, prior conservative therapies and their durations, imaging or diagnostic studies, targeted nerve and laterality, prior responses to interventions (e.g., injections), and intended ablation modality (e.g., radiofrequency, cryoneurolysis). Where CPT 64640 is billed, clarify the specific technique used since 64640 is nonspecific for method.

Clinical Background and Rationale

Radiofrequency ablation (RFA) and cryoneurolysis are minimally invasive procedures intended to reduce peripheral pain by disrupting nerve conduction. RFA uses thermal coagulation to create lesions that destroy peripheral sensory nerve endings, while cryoneurolysis applies very low temperatures (approximately -20° to -100°C) to induce Wallerian degeneration with preservation of perineural structures and recovery of nerve function over months. Coverage and medical necessity determinations depend on the specific indication and product.

Definitions

inv-27: Radiofrequency ablation (RFA) definition

TermRadiofrequency ablation (RFA)

DefinitionA minimally invasive method using a needle electrode and high-frequency electrical current to coagulate tissue and create a thermal lesion intended to destroy peripheral sensory nerve endings to alleviate pain; includes cooled RFA variants.

MechanismThermal coagulation/heat (coagulation necrosis) produced around the needle electrode; cooled RFA uses a water-cooled probe to apply more energy with less off-target tissue damage.

DistinctionDistinct from pulsed RF; pulsed RF is thought to cause less nerve destruction and its mechanism is uncertain.

inv-28: Cryoneurolysis definition

TermCryoneurolysis

Conservative Care and Staging Before Ablation

Conservative treatment requirements (top-level placeholder)

Conservative Treatment Requirements (overview): Conservative therapies appropriate to the condition should be attempted before considering minimally invasive ablation procedures when consistent with the member's Benefit Booklet/Evidence of Coverage; document review does not specify rigid top-level durations for all indications.

Refer to benefit booklet/Evidence of Coverage for applicable prior-treatment or step therapy requirements.

Conservative care typically tried first; staged escalation ~3 months described

Initial Conservative Care for Morton Neuroma and Similar Conditions: Begin with conservative management such as education, footwear modification, metatarsal pads, and orthotic devices to reduce pressure and irritation of the affected nerve.

Staged escalation protocols described in case series progress from footwear/modifications to steroid or local anesthetic injections, and then to surgery if prior stages are not relieved within approximately 3 months.

Frequency and Repeat Treatment Notes

inv-35: Prior authorization implies review of frequency per plan-specific rules

StatementPrior authorization is required for Medicare Advantage Plans and recommended for Commercial Products via the online tool for participating providers.

Implication for frequencyApproval via prior authorization includes review of frequency and appropriateness per plan-specific rules and benefit booklet/Evidence of Coverage.

DocumentationProviders must follow the online prior authorization tool criteria and demonstrate medical necessity per the Medical Necessity policy when applicable.

inv-36: Genicular RFA and cryoneurolysis — no explicit frequency limits provided in this excerpt

ScopeGenicular nerve ablation (RFA) and cryoneurolysis for knee osteoarthritis are addressed in randomized trials and systematic reviews with follow-up up to 12 months but methods and comparators are heterogeneous.

Imaging and Procedural Guidance

Note

Refer to Benefit Booklet/Evidence of Coverage for pre-procedure imaging requirements

Refer to the member's Benefit Booklet or Evidence of Coverage for any required pre-procedure imaging; this policy excerpt does not specify formal pre-procedure imaging mandates.

Confirm imaging requirements (if any) via the Benefit Booklet/Evidence of Coverage prior to scheduling.

Note

Imaging guidance commonly used for alcohol injection and RFA (ultrasound or fluoroscopy)

Although not mandated in this excerpt, ultrasound or fluoroscopic guidance is often used for procedures such as alcohol injection and RFA and was used in many trials for prognostic/anesthetic blocks.

Document imaging guidance used (ultrasound or fluoroscopy) in the procedure note as it may affect procedural accuracy and outcomes.

Note

Imaging techniques cited in literature (ultrasound, MR) — document if used

Procedures Considered Not Covered / Not Medically Necessary

The policy states that cryoneurolysis for knee OA/TKA and ablation (RFA, cryo, or intralesional alcohol) for Morton and other peripheral neuromas are not covered for Medicare Advantage and are not medically necessary for Commercial Products because available evidence is insufficient to demonstrate improvement in net health outcomes; providers should expect these services to be denied when billed for these indications unless benefit language differs in the member's contract.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAblation of Peripheral, Genicular and Other Nerves and Neuromas

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 5, 2026

Next Review DateJan 1, 2026

Key ActionObtain prior authorization via the online tool for Medicare Advantage members (recommended for Commercial) and document medical necessity per the online criteria.

SourceLink

On This Page

Two small RCTs and a meta-analysis report inconsistent pain benefit with significant heterogeneity and low-quality evidence; insufficient to determine net health outcome improvement.

insufficient certainty

Larger, longer trials needed.

Occipital Neuralgia / Cervicogenic Headache - RFA or Cryoneurolysis: Evidence is limited; no high-quality RCTs for chronic occipital neuralgia and available RCTs for cervicogenic headache are low quality or show only temporary benefit; insufficient to establish net health benefit.insufficient certainty

Placebo effects and need for sham-/active-controlled trials noted.

Morton Neuroma - Intralesional Alcohol, RFA, Cryoablation: Available literature is mainly retrospective case series and heterogeneous reports; no controlled trials demonstrate durable improvement in net health outcomes; evidence insufficient for coverage.insufficient certainty

Case series report some symptom relief but variability in protocols and lack of comparative data.

Peripheral Neuromas Other Than Morton: No published literature identified for ablation of other peripheral neuromas in this review; evidence is insufficient to determine net health benefit.no evidence

No controlled data found.

Include documentation that criteria in the online tool are met.
Clarify procedure technique when billing CPT 64640.
Attach supporting clinical records (progress notes, imaging, procedure reports).

Note

Benefit Verification

Verify member-specific benefits, eligibility, and any product-specific coverage restrictions before obtaining authorization or performing services. Benefits may vary by group and contract; refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable surgery and not medically necessary/not covered benefits.

Contact the provider call center for member-specific benefit questions.
Do not assume coverage — confirm whether the service is a covered benefit for the member's plan.

Note

Conservative Therapy Before Ablation

Conservative therapy is expected prior to consideration of ablation for conditions such as Morton neuroma and other peripheral nerve pain. Typical initial measures include footwear modification, metatarsal pads, orthotic devices, activity modification, and when appropriate, diagnostic or therapeutic injections. Document duration and response to conservative care in the medical record and authorization submission.

Examples: metatarsal pads, orthotics, footwear modification, activity modification.
Document trials and responses to conservative measures prior to ablation consideration.

Denial Risk

Explicit Noncoverage Triggers

Explicit noncoverage and not medically necessary triggers must be observed: cryoneurolysis for knee osteoarthritis or total knee arthroplasty is not covered for Medicare Advantage and not medically necessary for Commercial Products; radiofrequency ablation or cryoneurolysis for occipital neuralgia or cervicogenic headache is not covered for Medicare Advantage and not medically necessary for Commercial Products; minimally invasive ablation procedures (including intralesional alcohol injection, radiofrequency ablation, cryoablation) for Morton and other peripheral neuromas are not covered for Medicare Advantage and not medically necessary for Commercial Products.

Cryoneurolysis for knee osteoarthritis or TKA: MA - not covered; Commercial - not medically necessary.
RFA or cryoneurolysis for occipital neuralgia/cervicogenic headache: MA - not covered; Commercial - not medically necessary.
Minimally invasive ablation (alcohol injection, RFA, cryoablation) for Morton/other neuromas: MA - not covered; Commercial - not medically necessary.

Billing Rule

Product-Specific Coverage Restrictions and Coding

Product-specific coverage restrictions and coding guidance: CPT 64640 may be considered medically necessary for MA and Commercial when online-tool criteria are met but requires technique clarification. CPT 64624 (genicular nerve branches with imaging guidance) is covered for MA but is not medically necessary for Commercial Products. The following codes are not covered for MA and not medically necessary for Commercial Products: 64632, 0440T, 0441T, 0442T. Certain HCPCS device codes (C9808, C9809) may be considered medically necessary for Medicare Advantage only when device and procedure meet Medicare nonopioid device criteria and the Medical Necessity policy.

Covered when criteria met: 64640 (clarify technique).
MA covered / Commercial not medically necessary: 64624.
Not covered (MA) / not medically necessary (Commercial): 64632, 0440T, 0441T, 0442T.
MA only (when criteria met and Medicare device rules apply): C9808, C9809.

Denial Risk

Provider Responsibilities and Financial/Denial Risk Notice

Providers should confirm member-specific authorization requirements, coverage, and any potential financial liability for services determined not medically necessary. If services are denied or determined to be non-covered, providers may not bill the member except as allowed by the subscriber agreement and only after obtaining the member's written agreement to accept financial responsibility.

Confirm prior authorization approval prior to performing service.
Obtain and document member's written agreement if member will be billed for a non-covered service.

DefinitionApplication of very low temperatures (approximately -20°C to -100°C) to a nerve producing Wallerian (anterograde axonal) degeneration with disruption of nerve conduction while preserving perineural and epineural structures; allows regeneration and recovery of nerve function in about 3–5 months.

Example deviceiovera° cryoablation system — a portable handheld device for percutaneous targeted delivery of cold to superficial peripheral nerves.

inv-29: Neuroma / Morton neuroma definition

TermNeuroma / Morton neuroma

General neuroma definitionA pathology of a peripheral nerve arising as part of the reparative process after nerve injury or chronic irritation; may present within 1–12 months after injury and can be painful due to traction, compression, ischemia, or ectopic ion channel activity.

Morton neuroma specificsA common compression neuropathy of the common digital nerve in the forefoot, histologically characterized by perineural fibrosis, endoneurial edema, and axonal degeneration; typically located between the 3rd and 4th metatarsal heads and more common in women around age 50.

inv-30: Neuroma definition (alternate)

TermNeuroma

DefinitionPathology of a peripheral nerve developing as part of a normal reparative process after injury or chronic irritation; typically appears weeks to months after trauma, may enlarge over years, and can cause neuropathic pain triggered by touch or temperature.

Typical timelineOften appears 6–10 weeks after trauma with most presenting within 1–12 months; may gradually enlarge over 2–3 years.

inv-31: Morton neuroma definition (alternate)

TermMorton neuroma

DefinitionA painful compression neuropathy of the common digital nerve of the foot (also called interdigital neuroma) characterized by perineural fibrosis, endoneurial changes, and local vascular proliferation; pain is typically throbbing, burning, or shooting and localized to the plantar aspect between metatarsal heads.

Clinical featuresMore common in women (~10x), average age ~50; aggravated by narrow/toe box or high-heel shoes and often relieved by removing tight footwear.

Staged Escalation Preceding Ablation: If symptoms persist after initial conservative measures, consider corticosteroid or local anesthetic injections as the next step; progression to surgical or minimally invasive ablation approaches in the literature occurred after about 3 months of unsuccessful conservative care in staged care protocols.~3 months

Case series (eg, Bennett et al) described a 3-stage protocol with advancement to surgery if stages I–II fail within 3 months.

Additional conservative-treatment-related notes and references

Additional Notes on Conservative Treatments and Evidence: The referenced literature (systematic reviews, RCTs, and case series) includes conservative and interventional treatments across indications; specific conservative therapy durations and mandatory prerequisites for all ablation procedures are not prescribed in this excerpt.

References include randomized and observational studies as well as multiple case series for neuroma treatments; clinicians should document prior conservative treatments consistent with evidence and member benefits.

No explicit frequency limits for genicular RFA or cryoneurolysis are provided in this excerpt; frequency would be subject to prior authorization and plan-specific rules.

Evidence noteStudies report short-term benefits (3–6 months) with heterogeneity; longer blinded trials with ≥12 months follow-up are needed to determine net health outcome improvement.

inv-37:

Policy caveatThis medical policy is informational and not a guarantee of payment; benefits and eligibility are determined by the member's subscriber agreement or employer agreement which supersede this policy.

Authorization verificationFor member-specific benefits or authorization requirements, contact the provider call center.

Charges for non-covered servicesProviders may not charge members for services determined not medically necessary unless the member was informed and agreed in writing in advance.

Referenced studies mention use of ultrasound and MR guidance for cryoneurolysis and alcohol injections, but this policy excerpt does not establish these as formal requirements—document any imaging modality used in the record.

When using ultrasound or MR guidance, include imaging documentation in the clinical record to support technique and accuracy.